Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price increased by Royal Bank of Canada from $160.00 to $170.00 in a research note released on Monday, The Fly reports.
Several other research firms have also commented on JAZZ. TheStreet upgraded Jazz Pharmaceuticals from a c+ rating to a b rating in a research note on Thursday, August 20th. JPMorgan Chase & Co. assumed coverage on Jazz Pharmaceuticals in a research note on Monday. They set an overweight rating and a $175.00 price objective for the company. BidaskClub upgraded Jazz Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, September 1st. Barclays reiterated a buy rating on shares of Jazz Pharmaceuticals in a research note on Thursday, August 6th. Finally, Bank of America boosted their target price on Jazz Pharmaceuticals from $165.00 to $167.00 and gave the stock a buy rating in a report on Thursday, June 18th. Two analysts have rated the stock with a sell rating, two have given a hold rating and sixteen have assigned a buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $161.81.
Shares of Jazz Pharmaceuticals stock opened at $144.13 on Monday. The company has a quick ratio of 5.39, a current ratio of 5.62 and a debt-to-equity ratio of 0.66. Jazz Pharmaceuticals has a twelve month low of $86.88 and a twelve month high of $154.24. The business has a 50-day moving average price of $126.56 and a 200 day moving average price of $113.84. The firm has a market cap of $7.99 billion, a PE ratio of 62.39, a P/E/G ratio of 1.39 and a beta of 1.26.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, August 4th. The specialty pharmaceutical company reported $3.71 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.11 by $0.60. Jazz Pharmaceuticals had a return on equity of 20.47% and a net margin of 6.01%. The company had revenue of $562.44 million during the quarter, compared to analyst estimates of $503.19 million. During the same period in the previous year, the business earned $4.05 EPS. Jazz Pharmaceuticals’s quarterly revenue was up 5.3% on a year-over-year basis. On average, sell-side analysts expect that Jazz Pharmaceuticals will post 11.08 EPS for the current year.
In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 500 shares of the company’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $134.90, for a total transaction of $67,450.00. Following the transaction, the chief executive officer now directly owns 336,680 shares in the company, valued at $45,418,132. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 3,863 shares of company stock worth $503,644 over the last 90 days. 4.60% of the stock is owned by insiders.
Several institutional investors have recently made changes to their positions in JAZZ. Comerica Bank lifted its stake in shares of Jazz Pharmaceuticals by 19.5% in the 1st quarter. Comerica Bank now owns 3,112 shares of the specialty pharmaceutical company’s stock worth $334,000 after purchasing an additional 507 shares during the period. SG Americas Securities LLC purchased a new stake in Jazz Pharmaceuticals during the 1st quarter valued at approximately $408,000. Nissay Asset Management Corp Japan ADV lifted its position in Jazz Pharmaceuticals by 2.2% during the first quarter. Nissay Asset Management Corp Japan ADV now owns 5,734 shares of the specialty pharmaceutical company’s stock valued at $572,000 after purchasing an additional 121 shares during the last quarter. New York State Common Retirement Fund raised its position in shares of Jazz Pharmaceuticals by 18.1% during the 1st quarter. New York State Common Retirement Fund now owns 130,919 shares of the specialty pharmaceutical company’s stock valued at $13,058,000 after buying an additional 20,020 shares in the last quarter. Finally, Rhumbline Advisers raised its position in shares of Jazz Pharmaceuticals by 10.7% during the 1st quarter. Rhumbline Advisers now owns 72,658 shares of the specialty pharmaceutical company’s stock valued at $7,247,000 after buying an additional 7,051 shares in the last quarter. 92.82% of the stock is owned by institutional investors and hedge funds.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Further Reading: Economic Reports
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.